Weave Bio and Takeda Expand AI Automation Across Drug-Development Regulatory Workflows

Weave Bio announced a collaboration with Takeda to deploy its AI-native regulatory automation platform across 14 active drug-development programs in multiple global markets.

The collaboration began with AI-assisted preparation of Investigational New Drug (IND) submissions and expanded to Health Authority Question (HAQ) and Response to Question (RTQ) workflows.

A joint study reported that AI-assisted drafting reduced time to first draft for evaluated IND nonclinical summaries by about 97%—from roughly 100 hours to approximately 2.6–3.7 hours.

The study reported approximately 95% faithfulness to source data and no critical regulatory errors in independently reviewed AI-generated drafts, while emphasizing the continued need for expert human review.

The partnership highlights a broader industry shift toward using AI to automate regulatory writing, document verification, workflow tracking, and health-authority communications without removing human oversight.